Ardelyx Reports Real-World Phosphate Reductions With XPHOZAH Across Phosphate Binder Groups In Dialysis Patients, Presented At The ASN Kidney Week 2026
Real-world analysis showed serum phosphate reductions following XPHOZAH initiation across all phosphate binder groups evaluatedAdditional data highlighted the challenges of managing hyperphosphatemia and the morbidity
Ardelyx's phosphate medicine XPHOZAH worked in real patients. When doctors look at results, they can better understand if the treatment helps people stay healthier.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.